StreetAlpha.app
Home › Stocks › REGN

Regeneron Pharmaceuticals, Inc. (REGN)

Healthcare
$957.76
▲ +0.56%
LAST CLOSE · NOV 17

Regeneron is a New York biotechnology company that makes medicines for eye diseases, cancer, allergic conditions, and other serious illnesses. It last closed at $957.76 on Nov 17, up 0.56% on the day. REGN reports earnings on Thu, Jan 28, 2027. The average 12-month price target from 21 analysts is $961.52 (+0.4% from the last close), with a high of $1175.00 and a low of $812.00. Analyst consensus is Buy, based on the latest ratings from 21 firms (14 buy, 7 hold, 0 sell). Over the past 90 days StreetAlpha recorded 7 whale options trades in REGN, 43% of them bullish and 57% bearish. In the past 30 days there were 23 dark pool prints totaling $26.3M, the largest $3.7M.

AI Auto Pilots
Is REGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$16.9B
+18.6% vs a year ago
Net income
$4.8B
+5.2% vs a year ago
EPS (diluted)
$45.24
+8.4% vs a year ago
Free cash flow
$3.8B
22.6% margin
Balance sheet
Cash & equivalents
$3.7B
At Sep 30
Debt
$2.0B
At Sep 30
Shareholder equity
$33.5B
Buybacks
$3.0B
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $16.1B$16.1BFY2021FY2022: $12.2B$12.2BFY2022FY2023: $13.1B$13.1BFY2023FY2024: $14.2B$14.2BFY2024FY2025: $14.3B$14.3BFY2025

From REGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Next report
Jan 28
2027 · Time not announced
Consensus EPS forecast
$25.39
$5.85B revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Buy
Based on 21 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
21firms
14 Buy7 Hold0 Sell
Each firm's latest rating on REGN in the past 90 days
Average 12-month target
$961.52
▲ 0.4% upside

Based on 21 analysts who set a price target on REGN in the past 90 days. The average target is $961.52, with a high of $1175.00 and a low of $812.00, compared with the last close of $957.76.

Low $812.00Avg $961.52High $1175.00
Blue marker: last close $957.76
Highest target$1175.00
Average target$961.52
Lowest target$812.00
Latest rating changes
BarclaysMaintained
Nov 17Buy$1075
Leerink PartnersTarget raised
Nov 2Hold$824 → $997
BernsteinMaintained
Nov 2Hold$812
Morgan StanleyTarget raised
Nov 2Hold$779 → $855
RBC CapitalTarget raised
Nov 2Hold$810 → $913
DateFirmActionRatingPrice target
Nov 17BarclaysMaintainedBuy$1075
Nov 2Leerink PartnersTarget raisedHold$824 → $997
Nov 2BernsteinMaintainedHold$812
Nov 2Morgan StanleyTarget raisedHold$779 → $855
Nov 2RBC CapitalTarget raisedHold$810 → $913
Loading…

Technical Analysis

REGN · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 7% above its 20 day and 14% above its 50 day average. It is 22% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 68), near overbought. The nearest support is the Pivot at $956.73, and the nearest resistance the Pivot R1 at $966.51.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 3.2%/day
Key levels
$991.7352 week high+3.5%
$981.55Swing high (Nov 12)+2.5%
$966.51Pivot R1+0.9%
$957.76Last close
$956.73Pivot−0.1%
$947.97Pivot S1−1.0%
$894.9120 day average−6.6%
$887.22Swing low (Nov 6)−7.4%
$821.6150 day average−14.2%
$781.51100 day average−18.4%
$748.97200 day average−21.8%
$591.5252 week low−38.2%
Indicators
RSI (14)68.25Strong, overbought above 70Neutral
MACD42.26Above its signal lineBullish
Stochastic80.4Near the top of its rangeOverbought
ADX (14)39.4Trending up
Williams %R-18.9Oversold below −80, overbought above −20Overbought
CCI (20)73.5Oversold below −100, overbought above 100Neutral
Rate of change−1.6%Change over 10 sessionsBearish
ATR (14)$30.45Typical daily range, 3.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for REGN

What happened before

See how REGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed3 bullish and 4 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow REGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How REGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
7
Bullish
3
43%
Bearish
4
57%
Date span
Sep 11 – Nov 10
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
23
Notional
$26.3M
Largest print
$3.7M
Loading…

REGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲754 buying vs 553 selling
  • ▼Shares held by funds -3.5%
  • ▲Funds holding +80
  • ▲Superinvestors: 4 added, 1 cut
  • ▲Put/call 1.06 to 0.98
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding1,4231,343+6.0%
In funds' top 10159+66.7%
Held by funds–––
New / increased191 / 563112 / 483+26.7%
Reduced / sold out460 / 93536 / 169−21.6%
Put/call ratio0.981.06−7.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See REGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

REGN Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$3.0B
3.1% yield
Left in program
$2.2B
2.2% of value
Shares outstanding, 12 months
−1.8%
Fewer shares
Last quarter
$381.4M
Sep 2026
Avg price paid, last quarter
$663.22
575K shares bought
S&P 500 rank by spending
#79 of 358
 
Spent each quarter, last 3 yearsTop bar $1.2B
Dec 2023: $693.5M, average price $833.90Mar 2024: $300.1M, average price $954.73Jun 2024: $614.1M, average price $968.04Sep 2024: $746.4M, average price $1114.67Dec 2024: $1.2B, average price $806.29Mar 2025: $1.0B, average price $688.26Jun 2025: $1.1B, average price $550.45Sep 2025: $660.3M, average price $562.89Dec 2025: $899.2M, average price $681.24Mar 2026: $802.2M, average price $764.64Jun 2026: $1.2B, average price $666.12Sep 2026: $381.4M, average price $663.22
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 30, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether REGN is in one of them and how their past REGN trades turned out.

REGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered REGN in an article yet. Here's the latest on the wider market.

REGN Congress Trades

All congress trades →
Trades, 12 months
21
Buys
13
62%
Sells
8
38%
People
6
Last filed Nov 5
Who traded REGN · since 2014
Latest 5 filings of 136
$1K – $15KTraded Oct 7, 2026Filed Nov 5, 2026
$1K – $15KTraded Sep 4, 2026Filed Oct 7, 2026
$50K – $100KTraded Jul 23, 2026Filed Sep 22, 2026
$1K – $15KTraded Jul 17, 2026Filed Sep 22, 2026
$1K – $15KTraded Jul 7, 2026Filed Aug 7, 2026
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CABuy$1K – $15KOct 7, 2026Nov 5, 202629 d
Ro KhannaD · CASell$1K – $15KSep 4, 2026Oct 7, 202633 d
Donald J TrumpExecutive branchBuy$50K – $100KJul 23, 2026Sep 22, 202661 d
Donald J TrumpExecutive branchBuy$1K – $15KJul 17, 2026Sep 22, 202667 d
Ro KhannaD · CABuy$1K – $15KJul 7, 2026Aug 7, 202631 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Regeneron Pharmaceuticals

Regeneron is a biotechnology company based in Tarrytown, New York. It discovers, develops, makes, and sells medicines for people with serious diseases. Its products and product candidates address conditions such as eye disorders, allergic and inflammatory diseases, cancer, and cardiovascular and metabolic diseases. The company also covers neurological diseases, blood conditions, infectious diseases, and rare diseases. Its customers include patients and medical professionals.

Headquarters
Tarrytown, NY
Founded
1988